FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma
- Conditions
- OligodendrogliomaOligoastrocytomaAstrocytoma
- Registration Number
- NCT01089244
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Brief Summary
The aim of the study is to compare the two imaging modalities perfusion weighted MR-imaging and FET-PET in their ability to provide an accurate histological evaluation of low grade glioma and to reveal focal abnormalities within a homogeneously appearing tumor. Additionally, therapeutic effects should be assessed during a time period of two years.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
- neuroradiologically suspected low grade glioma (Astrocytoma WHOI-II, Oligodendroglioma WHO II, Oligoastrocytoma WHO II)
- histological verification will be obtained either by microsurgery or by stereotactic biopsy
- patients older than 18 years
- Karnofsky Performance Score >=70
- pregnant or nursing female patients will not be included in this study
Exclusion Criteria
- patients in whom informed consent cannot be obtained due to organic brain syndrome or insufficient language skills
- patients who cannot lie quiet for a time period of app. two hours during the FET-PEt scan
- medical history of a metastatic brain disease
- patients in whom an MRI scan cannot be performed due to claustrophobia metallic protheses or pacemakers etc.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival 24 months
- Secondary Outcome Measures
Name Time Method Progression Free survival 24 months
Trial Locations
- Locations (2)
University Hospital Munich, Department of Neurosurgery
🇩🇪Munich, Bavaria, Germany
University Hospital, Duesseldorf
🇩🇪Duesseldorf, North Rhine-Westphalia, Germany